- Aseptic Sampling Market Financial Growth and Impact Analysis.
According to the new market research report "Aseptic Sampling Market by Type (Manual [Type (Traditional, Single-use), Product (Bags, Bottles, Syringes, Accessories)], Automatic), Application (Upstream, Downstream), Technique (Off-line, On-line), End User (R&D, CMO, CRO) - Global Forecast to 2025", published by MarketsandMarkets™, the Aseptic Sampling Industry is projected to grow at a CAGR of 12.4% during the forecast period to reach USD 474 million by 2025 from USD 264 million in 2020.
Download PDF Brochure:
Factors such as the increasing demand for biopharmaceuticals, stringent government regulations to ensure drug safety, and funding to support life sciences research activities are driving the growth of this market.
The off-line technique segment accounted for the largest share of the aseptic sampling market.
Based on the technique, the aseptic sampling industry is segmented into off-line, at-line, and on-line technologies. The off-line segment accounted for the largest share of the aseptic sampling industry in 2019. Off-line sample collection is a traditional and widely used method of collecting samples aseptically, which is the primary factor responsible for the large share of this market segment.
Browse in-depth TOC on "Aseptic Sampling Market"
158 – Tables
29 – Figures
138 – Pages
The upstream processessegment accounted for the largest share of the aseptic sampling market in 2019.
Based on the application, the aseptic sampling industry is segmented into p into upstream processes and downstream processes. In 2019, the upstream processes segment dominated this market. Being the start of bioproduction, upstream processes form a key application area for aseptic sampling. Any contamination originating from the upstream process will be carried to the following procedures and affect overall production, leading to failure. Their importance in this stage is the key factor supporting the use of aseptic sampling products.
Europe dominate the aseptic sampling market during the forecast period
In 2019, Europe dominated the aseptic sampling industry, followed by Europe. The major factors driving the growth of this market include the patent cliff of several biologic drugs in the region. As a result, several companies in Europe are engaged in research activities for the development of novel drug products. In addition to this, governments in several European countries are supporting pharmaceutical companies to launch new biologic therapies that offer superior efficacy than traditional drugs. This, in turn, is increasing the number of R&D activities in the region and supporting the uptake of aseptic sampling products.
The prominent players in this market include Sartorius Stedim Biotech (France), Merck Millipore (Germany), Danaher Corporation (US), and Thermo Fisher Scientific (US). Other key players include Saint-Gobain (France), GEA Group (Germany), Avantor, Inc. (US), QualiTru Sampling Systems (US), Keofitt (Denmark), GEMÜ Group (US), W. L. Gore & Associates (US), Flownamics Analytical Instruments, Inc. (US), Lonza (Switzerland), and Trace Analytics (US).
Request Sample Report:
Merck KGaA is one of the leading players in the aseptic sampling industry.The company offers a strong portfolio of aseptic sampling products for biopharmaceutical manufacturing and process development. The company’s focus on inorganic growth strategies is evident from its recent partnership with Schneider Electric (France) to automate biopharmaceutical processes in the biopharmaceutical industry in China. Furthermore, Merck has a well-organized supply chain that delivers standard products in 24 to 48 hours worldwide. The company also focuses on the high-growth Asia region to increase its market share and revenue.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.